Welcome to our dedicated page for Ocular Therapeutix news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix stock.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company dedicated to enhancing vision and quality of life through the development, manufacturing, and commercialization of innovative ocular therapies. The company employs its proprietary hydrogel-based formulation technology to address various diseases and conditions affecting the eye.
The company's lead product, DEXTENZA® (dexamethasone insert), an FDA-approved corticosteroid, is designed for intracanalicular use to treat ocular inflammation and pain following ophthalmic surgery and ocular itching due to allergic conjunctivitis. DEXTENZA delivers dexamethasone to the ocular surface for up to 30 days without preservatives, resorbing naturally, eliminating the need for removal.
Ocular Therapeutix’s pipeline includes several promising candidates. OTX-TIC (travoprost intracameral implant) is in Phase 2 trials for treating open-angle glaucoma and ocular hypertension. Another key candidate is AXPAXLI™ (axitinib intravitreal implant), currently in Phase 3 trials for wet age-related macular degeneration (AMD) and Phase 1 trials for non-proliferative diabetic retinopathy (DR). The company also has OTX-CSI (cyclosporine intracanalicular insert) and OTX-DED (dexamethasone intracanalicular insert) for dry eye disease.
Recently, Ocular Therapeutix announced positive Phase 1 results for AXPAXLI in diabetic retinopathy, accelerating its development to Phase 3. Moreover, recent strategic changes include the appointment of Dr. Pravin U. Dugel as the CEO, aiming to transform the company into a leading retina-focused biopharmaceutical entity.
Ocular Therapeutix has secured significant partnerships and funding to support the clinical development of its robust pipeline. These include a licensing agreement with AffaMed Therapeutics for the commercialization of DEXTENZA in Greater China and ASEAN markets.
Follow Ocular Therapeutix for the latest updates on their innovative pipeline and corporate developments via their website, LinkedIn, and Twitter.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will report its financial results for the first quarter ending March 31, 2023, on May 8, 2023. Following the earnings release, a live conference call is scheduled for 4:30 PM Eastern Time to discuss the results and provide a business update. Ocular Therapeutix specializes in innovative therapies for eye conditions, with its first commercial product, DEXTENZA®, FDA-approved for treating ocular inflammation and associated pain. The company is also advancing several clinical trials, including OTX-TKI for wet AMD, OTX-TIC for glaucoma, and treatments for dry eye disease.
FAQ
What is the current stock price of Ocular Therapeutix (OCUL)?
What is the market cap of Ocular Therapeutix (OCUL)?
What is Ocular Therapeutix’s main technology platform?
What is DEXTENZA® used for?
Which product is Ocular Therapeutix developing for open-angle glaucoma?
What is the status of AXPAXLI™ (OTX-TKI)?
Who is the current CEO of Ocular Therapeutix?
What recent partnerships has Ocular Therapeutix secured?
What are OTX-CSI and OTX-DED?
How long does DEXTENZA deliver medication?
What clinical trial results were recently announced for AXPAXLI?
What is the focus of Ocular Therapeutix?
